AmunBio

AmunBio is a clinical-stage biotechnology company focused on developing innovative oncolytic virus therapies to treat advanced solid tumors. The company's lead candidate, AMUN-003, is a proprietary, genetically engineered adenovirus designed to selectively infect and lyse cancer cells while stimulating a robust systemic anti-tumor immune response. By utilizing a chimeric viral capsid, AMUN-003 enhances tumor cell entry and overcomes common resistance mechanisms found in traditional viral therapies. AmunBio's platform technology originated from research at the Moffitt Cancer Center, emphasizing a dual approach of direct viral oncolysis and long-term immune activation. The company is currently evaluating its lead program in Phase 1 clinical trials for patients with refractory solid malignancies. Through its cutting-edge immunotherapy platform, AmunBio aims to provide transformative treatment options for cancer patients with limited clinical alternatives.